Sana Biotechnology Stock Jumps After Early Data on CAR T-Cell Therapy
By Zaeem Shoaib Sana Biotechnology's stock jumped after the company discussed early Phase 1 trial results from its SC291 CAR T-cell therapy at the JPMorgan...
Steven Harr Zaeem Shoaib Chief Executive Steven Harr Ardent Phase Article Normal Biotechnology Services
Source: marketwatch.com